Patent Approval: Inspira Technologies has received U.S. Patent approval for its low flow rates extracorporeal oxygenation system, which is central to the ART500 device aimed at a $20 billion market for advanced respiratory support.
Market Expansion: The ART500 system targets patients needing respiratory support who are not severe enough for traditional high-flow ECMO systems, thus expanding the potential market significantly.
CEO Statement: Dagi Ben-Noon, CEO of Inspira, emphasized that the patent strengthens their competitive advantage and supports their growth strategy, aiming to establish a new standard of care for patients globally.
Intellectual Property Strategy: The newly granted patent protects key functionalities of the ART500 until 2043, with plans for additional patents in major jurisdictions to enhance their intellectual property coverage.
IINN
$1.02+Infinity%1D
Analyst Views on IINN
About IINN
Inspira Technologies Oxy B.H.N Ltd, formerly Insense Medical Ltd, incorporated on February 27, 2018, is a specialty medical device company based in Israel. The Company is engaged in the research, development, manufacture, and marketing of respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV). It provides patients with acute respiratory distress syndrome to maintain spontaneous breathing and avoid the various risks associated with the use of MV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
